Affinage

Showing TNFRSF1B — TNFR2 is a alias.

TNFRSF1B

Tumor necrosis factor receptor superfamily member 1B · UniProt P20333

Length
461 aa
Mass
48.3 kDa
Annotated
2026-06-10
68 papers in source corpus 17 papers cited in narrative 18 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 8/8 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

TNFRSF1B (TNFR2/TNFR80/CD120b/p75) is a TNF receptor that operates largely as a cooperative, signal-modulating partner of TNFR1 (TNFR60), shaping cellular responses to TNF-α across cell death, inflammation, and immune activation (PMID:8996244, PMID:7544644). Its signaling depends on TRAF2: by recruiting and depleting functional TRAF2, TNFR2 co-stimulation removes TRAF2-dependent anti-apoptotic protection and selectively enhances TNFR1-induced cell death, a cross-talk specific to the TNFR1 pathway (PMID:9743381). TNFR2 preferentially responds to membrane-bound rather than soluble TNF, and this membrane-TNF-driven cooperative signaling redirects T-cell responses toward apoptosis (PMID:8996244), drives full tissue-factor induction in endothelial cells (PMID:7544644), and prolongs iNOS expression and nitric oxide output in macrophages by acting in concert with TNFR1 (PMID:9712914). Beyond cooperation with TNFR1, TNFR2 transduces distinct TRAF2-dependent signals: it is the primary signal-transducing receptor for TNF-mediated NK-cell cytotoxic activation (PMID:7543923), and it drives B-cell IgM secretion through a TRAF2 requirement that is non-interchangeable with CD40-derived TRAF2 signals, while diverging from CD40 in its NF-κB and JNK pathway usage (PMID:11907088, PMID:15485859). CRISPR knockout studies confirm that TNFR2 governs a transcriptional program distinct and non-redundant from TNFR1 (PMID:38138998). TNFR2 mediates necroptosis in irradiated PBMCs downstream of membrane TNF-α (PMID:31570701), and is required in astrocytes for normal hippocampal long-term potentiation, synaptic protein expression, and astrocyte calcium dynamics. The receptor's extracellular domain is shed to generate soluble TNF-neutralizing decoy receptor, with elastase mediating constitutive shedding from resting neutrophils and a metalloprotease contributing additional shedding upon stimulation (PMID:14572651); self-aggregation conferred by the intracellular domain lowers the TNF off-rate and enhances neutralizing capacity of soluble receptor forms (PMID:8807502). TNFRSF1B expression is itself regulated post-transcriptionally by lncRNA NEAT1, which stabilizes its mRNA to amplify NF-κB-driven inflammatory cytokine output (PMID:34268386).

Mechanistic history

Synthesis pass · year-by-year structured walk · 14 steps
  1. 1995 High

    Established that TNFR2 is not redundant with TNFR1 but cooperates with it, since full induction of endothelial tissue factor required simultaneous triggering of both receptors via membrane TNF.

    Evidence Receptor-specific agonistic/antagonistic antibodies and membrane-TNF coculture with tissue factor readout in HUVECs

    PMID:7544644

    Open questions at the time
    • Did not define the intracellular signaling adaptors mediating TNFR2's contribution
    • Mechanism of synergy at the receptor level unresolved
  2. 1995 High

    Identified TNFR2 as the dominant signal-transducing receptor for TNF-driven NK cytotoxicity, since NK cells express TNFR2 but not TNFR1 and only anti-TNFR2 abrogated IL-2-induced LAK activity.

    Evidence Receptor-specific antibody ligation/blockade and cytotoxicity assays in primary NK cells

    PMID:7543923

    Open questions at the time
    • Downstream signaling pathway for cytotoxic activation not mapped
    • No molecular link to specific effector machinery
  3. 1996 Medium

    Characterized the gene architecture and promoter, revealing transcription-factor elements consistent with regulated hematopoietic expression.

    Evidence Genomic library screening, restriction mapping, and promoter sequence analysis

    PMID:8702885

    Open questions at the time
    • Functional activity of individual promoter elements not tested
    • No link to specific physiological transcriptional regulators
  4. 1996 High

    Showed that the intracellular domain drives self-aggregation of soluble receptor forms, explaining how shed/soluble TNFR2 achieves potent TNF neutralization by lowering the ligand off-rate.

    Evidence Soluble TNFR2 constructs expressed in insect cells with SPR kinetics and TNF neutralization assays

    PMID:8807502

    Open questions at the time
    • Structural basis of aggregation not resolved
    • Relevance to membrane receptor signaling not addressed
  5. 1997 High

    Demonstrated that membrane-bound but not soluble TNF engages TNFR2 to cooperatively shift infected T-cell fate toward apoptosis, defining TNFR2 as a modulator of TNF responsiveness.

    Evidence Receptor-specific antibodies and non-cleavable membrane-TNF coculture with HIV production and death readouts in T cells and primary lymphocytes

    PMID:8996244

    Open questions at the time
    • Molecular basis of membrane-TNF preference not defined
    • Adaptor-level mechanism not established
  6. 1998 High

    Provided the molecular mechanism for TNFR2/TNFR1 cross-talk: TNFR2 depletes functional TRAF2 to abolish anti-apoptotic signaling and selectively enhance TNFR1-induced death.

    Evidence Wild-type and dominant-negative TRAF2 overexpression with JNK and cell-death assays in HeLa cells

    PMID:9743381

    Open questions at the time
    • Quantitative dynamics of TRAF2 depletion in primary cells not addressed
    • Did not test whether other TRAF members participate
  7. 1998 High

    Defined TNFR2 as a 'ligand-passer' that prolongs and potentiates TNFR1-driven iNOS/NO output rather than acting alone.

    Evidence Receptor-specific cross-linking and blocking antibodies with iNOS mRNA/protein and nitrite readouts in mouse macrophages

    PMID:9712914

    Open questions at the time
    • The additional sustained signaling event downstream of TNFR2 was not molecularly identified
    • Relationship to TRAF2 not tested in this system
  8. 2004 High

    Resolved how TNFR2 uses TRAF2 distinctly from CD40, showing partial TRAF2 dependence for IgM secretion but, unlike CD40, no TRAF2 requirement for JNK activation.

    Evidence TRAF2-deficient and dominant-negative B cells with chimeric CD40-CD120b receptors and NF-κB/JNK/IgM readouts

    PMID:11907088 PMID:15485859

    Open questions at the time
    • Non-TRAF2 adaptors mediating divergent NF-κB activation not identified
    • Mechanism rendering CD40-TRAF2 non-substitutable for TNFR2-TRAF2 unknown
  9. 2019 Medium

    Implicated TNFR2 as the primary driver of necroptosis in irradiated PBMCs via membrane TNF-α, linking this death modality to the secretome's pro-angiogenic activity.

    Evidence Transcriptome identification with necroptosis inhibition, cell-death morphology imaging, and aortic ring angiogenesis assay

    PMID:31570701

    Open questions at the time
    • Membrane-TNF involvement inferred rather than directly demonstrated
    • Necroptotic signaling components downstream of TNFR2 not mapped
  10. 2021 Medium

    Identified post-transcriptional control of TNFRSF1B by lncRNA NEAT1, which stabilizes its mRNA to amplify NF-κB-driven inflammatory cytokine production.

    Evidence RNA pulldown, RNA decay assays, knockdown/overexpression, and p65 translocation readouts in intestinal epithelial cells

    PMID:34268386

    Open questions at the time
    • Direct NEAT1-TNFRSF1B mRNA binding site not mapped
    • In vivo relevance not established
  11. 2023 Medium

    Confirmed via clean genetic ablation that TNFR2 and TNFR1 drive non-redundant transcriptional programs in response to TNF-α.

    Evidence CRISPR knockout of TNFRSF1A and TNFRSF1B in K562 cells with RNA-seq after TNF-α stimulation

    PMID:38138998

    Open questions at the time
    • Receptor-specific transcription factors driving divergence not pinned down
    • Single cell-line context
  12. 2024 Medium

    Extended TNFR2 function into oxidative-stress contexts, showing its blockade protects airway epithelial cells via an LTα/LTα3-TNFR2 axis.

    Evidence siRNA knockdown and etanercept treatment with viability readouts under oxidative stress in CF gland cells

    PMID:38539900

    Open questions at the time
    • Death pathway downstream of TNFR2 in this context not defined
    • LTα3-TNFR2 binding not directly demonstrated
  13. 2025 Medium

    Established a non-immune, CNS role: astrocytic TNFR2 is required for hippocampal LTP, synaptic protein expression, and astrocyte calcium dynamics, with cognitive consequences.

    Evidence Astrocyte-specific conditional TNFR2 knockout mice with electrophysiology, behavior, RNA-seq, and calcium imaging (preprint)

    Open questions at the time
    • Preprint, not yet peer-reviewed
    • Molecular link from TNFR2 to synaptic protein regulation not mechanistically defined
    • Basis of sex-dependent effects unknown
  14. 2025 Medium

    Defined a protective host-defense role for the receptor in vivo, since tnfrsf1b knockout zebrafish showed heightened infection susceptibility rescued by mRNA reintroduction.

    Evidence CRISPR knockout zebrafish with K. pneumoniae infection, mRNA rescue, and pharmacological TNFR blockade

    PMID:41170162

    Open questions at the time
    • Signaling pathway underlying protection not mapped
    • Translatability to mammalian immunity not addressed

Open questions

Synthesis pass · forward-looking unresolved questions
  • How TNFR2 ligand engagement (membrane vs soluble TNF, LTα) is converted into divergent context-specific outcomes—cooperative death, NK/B-cell activation, necroptosis, or synaptic support—through specific adaptor and downstream effector usage remains unresolved.
  • No structural model linking receptor oligomerization state to signaling output
  • Full TRAF2-independent adaptor repertoire unknown
  • Determinants of cell-type-specific outcome selection undefined

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0060089 molecular transducer activity 4 GO:0098772 molecular function regulator activity 2
Localization
GO:0005576 extracellular region 2 GO:0005886 plasma membrane 2
Pathway
R-HSA-168256 Immune System 4 R-HSA-162582 Signal Transduction 3 R-HSA-5357801 Programmed Cell Death 3 R-HSA-8953897 Cellular responses to stimuli 2
Partners
TNFRSF1ATRAF2

Evidence

Reading pass · 18 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1998 TNFRSF1B (TNFR80)-mediated enhancement of TNFR60-induced cell death requires TRAF2: TNFR80 costimulation depletes functional TRAF2 (which normally suppresses apoptosis downstream of TNFR60), thereby abolishing TRAF2-dependent anti-apoptotic signaling and selectively enhancing TNFR60-induced cell death. This cross-talk is specific to TNFR60 and does not affect Fas-, ceramide-, or TRAIL-induced death. Overexpression of wild-type and dominant-negative TRAF2 mutants in HeLa cells; receptor-specific antibody stimulation; JNK activation assays; cell death assays Journal of immunology High 9743381
1997 Simultaneous activation of both TNFR60 and TNFRSF1B (TNFR80) by membrane-bound TNF (but not soluble TNF) in HIV-infected T cells cooperatively shifts the response from HIV production toward induction of apoptosis, demonstrating that TNFRSF1B is an important modulator of TNF responsiveness via cooperative signaling with TNFR60. Receptor-specific agonistic and antagonistic antibodies; coculture with cells expressing non-cleavable membrane TNF; HIV production and cell death assays in ACH-2 cells and primary blood lymphocytes The Journal of experimental medicine High 8996244
1995 Both TNFRSF1B (TNFR80) and TNFR60 are required for full TNF-α-dependent tissue factor expression in human umbilical vein endothelial cells: selective triggering of either receptor alone partially induces tissue factor, but simultaneous activation of both is required for complete induction; membrane TNF-α drives synergistic signaling through both receptor types. Antagonistic and agonistic receptor-specific antibodies; coculture with cells expressing non-cleavable membrane TNF; tissue factor production assay in HUVECs Blood High 7544644
1995 TNFRSF1B (TNFR80/CD120b) is the primary signal-transducing receptor for TNF-mediated activation of NK cell cytotoxic function: purified NK cells (CD56+CD3−) express TNFR80 but not TNFR60; anti-TNFR80 antibody mimics TNF in enhancing NK cytotoxicity and, in combination with IL-2, supports lymphokine-activated killer development, whereas only anti-TNFR80 (not anti-TNFR60) abrogates IL-2-induced LAK activity. Monoclonal antibody-mediated receptor-specific ligation and blockade; NK cytotoxicity assays on K562 targets; flow cytometry; LAK cell assays Journal of leukocyte biology High 7543923
1998 TNFRSF1B (CD120b/p75) cooperates with CD120a (p55) to regulate nitric oxide and iNOS expression in mouse macrophages: CD120a ligation alone is necessary and sufficient for transient iNOS mRNA and NO production, but co-ligation of CD120b markedly prolongs iNOS mRNA and protein expression and potentiates NO accumulation, likely by acting as a 'ligand-passer' to CD120a and initiating an additional sustained signaling event. Antibody-mediated specific cross-linking of each receptor; iNOS mRNA quantification; NO2− measurement; iNOS protein western blot; blocking antibodies The Journal of biological chemistry High 9712914
2002 CD40-induced TNF-α secretion by B cells subsequently signals through TNFRSF1B (CD120b) to enhance IgM secretion; TRAF2 is required for CD120b-mediated IgM production, but TRAF2-dependent CD40 signals cannot substitute for TRAF2-dependent CD120b signals in this response, indicating distinct TRAF2 utilization by the two receptors. Dominant-negative TRAF2 overexpression; TRAF2-deficient B cells; anti-TNF blocking antibodies; IgM ELISA; CH12.LX B cell line Journal of immunology High 11907088
2004 CD40 and TNFRSF1B (CD120b) use primarily divergent mechanisms to activate NF-κB, but both partially require TRAF2 for IgM secretion; only CD40 (not CD120b) requires TRAF2 for JNK (c-Jun N-terminal kinase) activation, demonstrating that these two TNFR family members use distinct TRAF2-dependent pathways to mediate overlapping downstream events. Wild-type and TRAF2-deficient B cells expressing CD40 or hybrid CD40-CD120b molecules; NF-κB reporter assays; JNK kinase assay; IgM ELISA The Journal of biological chemistry High 15485859
1996 The intracellular domain of TNFRSF1B (TNFR80) promotes noncovalent self-aggregation of soluble receptor forms, which lowers the TNF off-rate and markedly increases TNF-neutralizing capacity compared to the monomeric extracellular domain alone. Production of multiple soluble TNFR80 constructs in insect cells; surface plasmon resonance (ligand off-rate kinetics); TNF bioactivity neutralization assays Journal of interferon & cytokine research High 8807502
2003 Elastase is the serine protease responsible for constitutive shedding of TNFRSF1B (TNF-R75) from resting human neutrophils, generating a 28-kDa receptor fragment; upon stimulation (TNF or fMLP), a metalloprotease additionally contributes to shedding and generates a 40-kDa fragment. Selective serine protease inhibitors (DFP, elastase-specific inhibitors, α1-protease inhibitor) and metalloprotease inhibitors; western blot detection of shed receptor fragments from neutrophil supernatants FEBS letters High 14572651
2019 TNFRSF1B is the primary driver of necroptosis in γ-irradiated peripheral blood mononuclear cells (PBMCs), most likely via membrane-bound TNF-α signaling; necroptosis (but not apoptosis) is required for the pro-angiogenic activity of the PBMC secretome. Necroptosis inhibition experiments; TNFRSF1B identification from transcriptome analysis; scanning electron microscopy and image stream analysis of cell death morphology; aortic ring angiogenesis assay Cell death & disease Medium 31570701
2021 LncRNA NEAT1 stabilizes TNFRSF1B mRNA (demonstrated by RNA pulldown co-precipitation and RNA decay assay), increasing TNFRSF1B protein levels, which in turn promotes NF-κB p65 nuclear translocation and downstream inflammatory cytokine (IL-8, MCP-1) expression in intestinal epithelial cells stimulated with TNF-α. RNA pulldown assay; RNA decay assay; siRNA knockdown and overexpression; western blot for TNFRSF1B and NF-κB p65; immunofluorescence for p65 translocation; ELISA for cytokines Annals of translational medicine Medium 34268386
2024 Galactosylceramide (GalCer) suppresses TNFRSF1B promoter activity and gene expression in breast cancer cells via a P53-dependent mechanism: cells with high GalCer express lower P53, and siRNA-mediated P53 knockdown phenocopies GalCer in reducing TNFRSF1B expression and promoter activity, linking GalCer-driven P53 suppression to downregulation of TNFRSF1B transcription. Promoter-luciferase reporter assays; siRNA knockdown of P53; western blot and RT-qPCR for TNFRSF1B expression in MDA-MB-231 and MCF7 cells with high vs. no GalCer Cancers Medium 38254878
2023 TNF-α inhibits chondrogenic differentiation of human adipose-derived stem cells by signaling through TNFRSF1B (TNFR2) to upregulate RELA (NF-κB p65) expression, which in turn increases OPA1 expression and promotes mitochondrial fusion. Gene microarray and RT-qPCR; western blot for TNFRSF1B, RELA, OPA1; Alcian blue and Sirius red staining for chondrogenesis; fluorescent mitochondrial imaging Journal of orthopaedic surgery and research Low 37312126
2023 TNFRSF1B (TNFR2) knockout in K562 cells produces distinct transcriptional profiles from TNFR1 knockout following TNF-α stimulation, with altered regulation of pathways associated with inflammation, apoptosis, and cell proliferation, demonstrating non-redundant roles of the two receptors in TNF-α-induced transcriptional responses. CRISPR knockout of TNFRSF1A and TNFRSF1B in K562 cells; RNA-seq transcriptome profiling after TNF-α stimulation International journal of molecular sciences Medium 38138998
2024 TNFRSF1B signaling blockade (siRNA knockdown or anti-TNF biologic etanercept blocking LTα3-TNFR2 axis) protects airway epithelial cells from oxidative stress-induced death; lymphotoxin-α (LTA) is overexpressed in airway epithelial cells under oxidative stress and serves as the relevant ligand activating TNFRSF1B in this context. siRNA knockdown of TNFRSF1B in CF submucosal gland cells; etanercept treatment; cell viability assays under oxidative stress; bioinformatic RNAi screen analysis Antioxidants Medium 38539900
2025 Selective ablation of TNFRSF1B (TNFR2) in astrocytes (GfapcreERT2:Tnfrsf1bfl/fl mice) impairs hippocampal long-term potentiation (LTP), disrupts expression of synaptic proteins (SNARE complex molecules, glutamate receptor subunits, glutamate transporters), increases glial reactivity, impairs astrocyte calcium dynamics, and causes cognitive deficits, with more pronounced effects in males than females. Conditional astrocyte-specific TNFR2 knockout mice; electrophysiology (LTP); behavioral cognitive assays; astrocyte RNA-seq; calcium imaging; immunostaining for synaptic and glial markers bioRxivpreprint Medium
2025 Tnfrsf1b knockout in zebrafish increases susceptibility to Klebsiella pneumoniae infection with elevated malformation/mortality, increased macrophage and neutrophil recruitment, and elevated pro-inflammatory cytokines (TNF-α, IL-1β); rescue by mRNA injection and overexpression in wild-type confers protection, establishing a protective role for tnfrsf1b in host defense. CRISPR/Cas9 tnfrsf1b knockout zebrafish; K. pneumoniae infection model; mRNA rescue injection; TNFR inhibitor (R7050) pharmacological blockade; qRT-PCR and ELISA for cytokines; immune cell staining Infection and drug resistance Medium 41170162
1996 The human TNFRSF1B gene spans ~43 kbp, consists of 10 exons and 9 introns, and its 5'-flanking promoter region contains consensus binding elements for transcription factors including T cell factor-1, Ikaros, AP-1, NF-κB, Sp1, IL-6RE, ISRE, GAS, and CK-2, consistent with regulated expression in hematopoietic cells. Genomic library screening; restriction mapping; DNA sequencing; promoter sequence analysis The Journal of biological chemistry Medium 8702885

Source papers

Stage 0 corpus · 68 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
1996 Human tumor necrosis factor receptor p75/80 (CD120b) gene structure and promoter characterization. The Journal of biological chemistry 129 8702885
1998 TNFR80-dependent enhancement of TNFR60-induced cell death is mediated by TNFR-associated factor 2 and is specific for TNFR60. Journal of immunology (Baltimore, Md. : 1950) 114 9743381
2002 Comment: the methionine 196 arginine polymorphism in exon 6 of the TNF receptor 2 gene (TNFRSF1B) is associated with the polycystic ovary syndrome and hyperandrogenism. The Journal of clinical endocrinology and metabolism 86 12161545
2019 MiR-125a-5p promotes osteoclastogenesis by targeting TNFRSF1B. Cellular & molecular biology letters 64 30976285
2012 Pharmacogenetic analysis of TNF, TNFRSF1A, and TNFRSF1B gene polymorphisms and prediction of response to anti-TNF therapy in psoriasis patients in the Greek population. Molecular diagnosis & therapy 63 22111980
2001 Analysis of the association of HLA-DRB1, TNFalpha promoter and TNFR2 (TNFRSF1B) polymorphisms with SLE using transmission disequilibrium test. Genes and immunity 62 11607787
1997 Membrane tumor necrosis factor (TNF) induced cooperative signaling of TNFR60 and TNFR80 favors induction of cell death rather than virus production in HIV-infected T cells. The Journal of experimental medicine 60 8996244
1995 Both tumor necrosis factor receptors, TNFR60 and TNFR80, are involved in signaling endothelial tissue factor expression by juxtacrine tumor necrosis factor alpha. Blood 57 7544644
2001 Tumor necrosis factor receptor 2 gene (TNFRSF1B) in genetic basis of coronary artery disease. Journal of molecular medicine (Berlin, Germany) 56 11357933
2013 Role of TNFRSF1B polymorphisms in the response of Crohn's disease patients to infliximab. Human immunology 52 24121042
2000 Identification of TNFRSF1B as a novel modifier gene in familial combined hyperlipidemia. Human molecular genetics 50 10958645
2012 Differential expression of TNFR1 (CD120a) and TNFR2 (CD120b) on subpopulations of human monocytes. Journal of inflammation (London, England) 46 23039818
2001 Regenerating soleus and extensor digitorum longus muscles of the rat show elevated levels of TNF-alpha and its receptors, TNFR-60 and TNFR-80. Muscle & nerve 41 11439381
1999 Distribution of TNF-alpha, TNF-R55 and TNF-R75 in the rheumatoid synovial membrane: TNF receptors are localized preferentially in the lining layer; TNF-alpha is distributed mainly in the vicinity of TNF receptors in the deeper layers. Scandinavian journal of immunology 38 10102645
2002 Linkage disequilibrium between polymorphisms in the human TNFRSF1B gene and their association with bone mass in perimenopausal women. Human molecular genetics 37 12217957
2014 Association of TNF-α, TNFRSF1A and TNFRSF1B gene polymorphisms with the risk of sporadic breast cancer in northeast Chinese Han women. PloS one 35 25010932
2021 LncRNA NEAT1 mediates intestinal inflammation by regulating TNFRSF1B. Annals of translational medicine 34 34268386
1995 Regulation of NK cells through the 80-kDa TNFR (CD120b). Journal of leukocyte biology 34 7543923
2014 The TNFRSF1B rs1061622 polymorphism (p.M196R) is associated with biological drug outcome in Psoriasis patients. Archives of dermatological research 33 25537528
2006 Expression of nerve growth factor and its receptors NTRK1 and TNFRSF1B is regulated by estrogen and progesterone in the uteri of golden hamsters. Biology of reproduction 33 16436532
2002 Role of TNF receptor-associated factor 2 in the activation of IgM secretion by CD40 and CD120b. Journal of immunology (Baltimore, Md. : 1950) 32 11907088
1998 Cooperative signaling by tumor necrosis factor receptors CD120a (p55) and CD120b (p75) in the expression of nitric oxide and inducible nitric oxide synthase by mouse macrophages. The Journal of biological chemistry 32 9712914
2009 Investigation of genetic variants within candidate genes of the TNFRSF1B signalling pathway on the response to anti-TNF agents in a UK cohort of rheumatoid arthritis patients. Pharmacogenetics and genomics 31 19262425
2005 No association with hypertension of CLCNKB and TNFRSF1B polymorphisms at a hypertension locus on chromosome 1p36. Journal of hypertension 31 16003175
2019 Tissue-regenerative potential of the secretome of γ-irradiated peripheral blood mononuclear cells is mediated via TNFRSF1B-induced necroptosis. Cell death & disease 28 31570701
2009 Cigarette smoking, STAT4 and TNFRSF1B polymorphisms, and systemic lupus erythematosus in a Japanese population. The Journal of rheumatology 27 19684152
2004 Role of tumor necrosis factor (TNF) receptor-associated factor 2 (TRAF2) in distinct and overlapping CD40 and TNF receptor 2/CD120b-mediated B lymphocyte activation. The Journal of biological chemistry 27 15485859
2015 Genetic variants within the TNFRSF1B gene and susceptibility to rheumatoid arthritis and response to anti-TNF drugs: a multicenter study. Pharmacogenetics and genomics 23 25850964
2004 Association between TNFRSF1B polymorphisms and bone mineral density, bone loss and fracture. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 23 15071724
1999 Preferential expression of tumor necrosis factor receptor 55 (TNF-R55) on human articular chondrocytes: selective transcriptional upregulation of TNF-R75 by proinflammatory cytokines interleukin 1beta, tumor necrosis factor-alpha, and basis fibroblast growth factor. The Journal of rheumatology 23 10090177
2023 Single-cell transcriptomics identify TNFRSF1B as a novel T-cell exhaustion marker for ovarian cancer. Clinical and translational medicine 22 37712139
2010 TNFRSF1B A1466G genotype is predictive of clinical efficacy after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. Journal of experimental & clinical cancer research : CR 22 20646319
2001 TNFRSF1B in genetic predisposition to clinical neuropathy and effect on HDL cholesterol and glycosylated hemoglobin in type 2 diabetes. Diabetes care 22 11315843
2023 MAIT cells confer resistance to Lenvatinib plus anti-PD1 antibodies in hepatocellular carcinoma through TNF-TNFRSF1B pathway. Clinical immunology (Orlando, Fla.) 21 37717672
2011 TNFRSF1B +676 T>G polymorphism predicts survival of non-small cell lung cancer patients treated with chemoradiotherapy. BMC cancer 21 21995493
2021 Exosomes Derived from Pancreatic Cancer Cells Induce Osteoclast Differentiation Through the miR125a-5p/TNFRSF1B Pathway. OncoTargets and therapy 19 33907416
2009 A functional haplotype in the 3'untranslated region of TNFRSF1B is associated with tuberculosis in two African populations. American journal of respiratory and critical care medicine 19 20007930
1996 Characterization of different soluble TNF receptor (TNFR80) derivatives: positive influence of the intracellular domain on receptor/ligand interaction and TNF neutralization capacity. Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 18 8807502
2009 Association analysis of TNFRSF1B polymorphisms with type 2 diabetes and its related traits in North India. Genomic medicine 16 19343543
2022 TNFRSF1B and TNF Variants Are Associated With Differences in Levels of Soluble Tumor Necrosis Factor Receptors in Patients With Severe COVID-19. The Journal of infectious diseases 15 35294530
2021 TNFRSF1B Gene Variants and Related Soluble TNFR2 Levels Impact Resilience in Alzheimer's Disease. Frontiers in aging neuroscience 14 33716716
2017 Genetic Susceptibility in Acute Pancreatitis: Genotyping of GSTM1, GSTT1, GSTP1, CASP7, CASP8, CASP9, CASP10, LTA, TNFRSF1B, and TP53 Gene Variants. Pancreas 14 27984487
2019 Polymorphisms in TNF Receptor Superfamily 1B (TNFRSF1B:rs3397) are Linked to Mycobacterium avium paratuberculosis Infection and Osteoporosis in Rheumatoid Arthritis. Microorganisms 13 31817071
2018 Association of TNFRSF1B Promoter Polymorphisms with Human Disease: Further Studies Examining T-Regulatory Cells Are Required. Frontiers in immunology 12 29559979
2018 Role of TNFRSF1A and TNFRSF1B polymorphisms in susceptibility, severity, and therapeutic efficacy of etanercept in human leukocyte antigen-B27-positive Chinese Han patients with ankylosing spondylitis. Medicine 11 30075559
2012 Association analysis of TNFRSF1B polymorphism with susceptibility for migraine in the Chinese Han population. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 11 22342236
2013 Predictive value of conjointly examined IL-1ra, TNF-R I, TNF-R II, and RANTES in patients with primary glomerulonephritis. Journal of Korean medical science 10 23400706
2011 No association of TNFRSF1B variants with type 2 diabetes in Indians of Indo-European origin. BMC medical genetics 10 21849023
2003 Evidence that elastase is the TNF-R75 shedding enzyme in resting human polymorphonuclear leukocytes. FEBS letters 10 14572651
2016 TNFRSF1B Is Associated with ANCA in IBD. Inflammatory bowel diseases 8 27104820
2024 TNFRSF1B Signaling Blockade Protects Airway Epithelial Cells from Oxidative Stress. Antioxidants (Basel, Switzerland) 7 38539900
2012 The methionine 196 arginine polymorphism of the TNF receptor 2 gene (TNFRSF1B) is not associated with worse outcomes in heart failure. Cytokine 7 22921902
2024 Galactosylceramide Upregulates the Expression of the BCL2 Gene and Downregulates the Expression of TNFRSF1B and TNFRSF9 Genes, Acting as an Anti-Apoptotic Molecule in Breast Cancer Cells. Cancers 6 38254878
2023 Knockouts of TNFRSF1A and TNFRSF1B Genes in K562 Cell Line Lead to Diverse Long-Lasting Responses to TNF-α. International journal of molecular sciences 6 38138998
2007 Bone structural effects of variation in the TNFRSF1B gene encoding the tumor necrosis factor receptor 2. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 6 18038243
1999 Expression of tumour necrosis factor receptors (CD120a and CD120b) on bronchoalveolar cells. Cytokine 5 10433809
2025 Genetic Polymorphisms on TNFA, TNFRSF1A, and TNFRSF1B Genes Predict the Effectiveness of Anti-TNF-α Treatment in Inflammatory Bowel Disease Patients. Biomedicines 4 40149645
2024 The Impact of ARMS2 (rs10490924), VEGFA (rs3024997), TNFRSF1B (rs1061622), TNFRSF1A (rs4149576), and IL1B1 (rs1143623) Polymorphisms and Serum Levels on Age-Related Macular Degeneration Development and Therapeutic Responses. International journal of molecular sciences 3 39273697
2025 The TNFRSF1B Connection: Implications for Androgenetic Alopecia Pathogenesis and Treatment. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2 40343723
2024 Impact of TNFRSF1B (rs3397, rs1061624 and rs1061622) and IL6 (rs1800796, rs1800797 and rs1554606) Gene Polymorphisms on Inflammatory Response in Patients with End-Stage Kidney Disease Undergoing Dialysis. Biomedicines 2 38927435
2023 TNF-α activates RELA expression via TNFRSF1B to upregulate OPA1 expression and inhibit chondrogenic differentiation of human adipose stem cells. Journal of orthopaedic surgery and research 2 37312126
2016 Analysis of differential β variable region of T cell receptor expression and NAV3/TNFRSF1B gene mutation in mycosis fungoides. Oncotarget 2 26918607
2016 Association of TNFRSF1B +676 gene polymorphism with the risk of rheumatoid arthritis in Han Chinese population in Hunan. Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences 2 27640805
2025 Association of the TNFRSF1B-rs1061622 variant with nonresponse to infliximab in ulcerative colitis. Scientific reports 1 40414945
2026 CTLA-4 and TNFRSF1B genetic variants in clinicopathological aspects and outcome of cutaneous melanoma. Melanoma research 0 42186386
2025 Tnfrsf1b Protects Zebrafish Against Klebsiella pneumoniae Infection. Infection and drug resistance 0 41170162
2021 Polymorphisms of the TNF, LTA, and TNFRSF1B genes are associated with onsets of menarche and menopause in US women of European ancestry. Annals of human biology 0 34595982
2017 Association of VNTR polymorphism of tumor necrosis factor receptor 2 (TNFRSF1B) with pulmonary tuberculosis. Molecular biology research communications 0 28447045

Missed literature

Know a paper Affinage missed for TNFRSF1B? Flag it for the maintainers and the community.

No submissions yet.